Interview with the Innovators

Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer

Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer.

Related Items

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: